Foghorn Therapeutics (FHTX) Current Assets (2019 - 2026)

Foghorn Therapeutics' Current Assets history runs 8 years deep, the most recent figure standing at $188.1 million for Q1 2026.

• In Q1 2026, Current Assets fell 16.57% year-over-year to $188.1 million; the TTM figure through Mar 2026 stood at $188.1 million (down 16.57% YoY), while the FY2025 annual figure was $163.2 million, down 34.6% from the prior year.
• Current Assets was $188.1 million for Q1 2026 at Foghorn Therapeutics, up from $163.2 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $429.8 million in Q1 2022 to a low of $163.2 million in Q4 2025.
• Historically, Current Assets has averaged $274.3 million across 5 years, with a median of $265.4 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Current Assets soared 204.76% in 2022, then slumped 34.6% in 2025.
• A 5-year view of Current Assets shows it stood at $351.4 million in 2022, then sank by 31.65% to $240.2 million in 2023, then advanced by 3.92% to $249.6 million in 2024, then plunged by 34.6% to $163.2 million in 2025, then increased by 15.21% to $188.1 million in 2026.
• The last three Current Assets figures came in at $188.1 million (Q1 2026), $163.2 million (Q4 2025), and $184.1 million (Q3 2025), per Business Quant data.